

1 High resolution imaging and five-year tuberculosis contact outcomes

2
3 Hanif Esmail*^{1,2,3}, M.B., Ch.B., Ph.D., Anna K Coussens*^{1,4,5}, Ph.D., Friedrich Thienemann^{1,6},
4 M.D., Bianca Sossen¹, M.B., Ch.B., M.Sc., Sandra L Mukasa¹, M.B., Ch.B., James Warwick⁷, M.B.,
5 Ch.B., Ph.D., Rene T. Goliath¹, M.Phil., Nashreen Omar Davies¹, D.D.R., Emily Douglass⁸, M.P.H.,
6 Amanda Jackson¹, B.Sc.(Hons), Francisco Lakay¹, M.Sc., Elizabeth Streicher⁹, Ph.D., Jacob E.
7 Munro^{5,10}, M.I.T., Marilou H Barrios^{5,11}, Ph.D., Torben Heinsohn¹², B.M., B.Ch., Liana
8 Macpherson², M.B., Ch.B., Dylan Sheerin^{4,5}, Ph.D., Saalikhaz Aziz¹, M.B., Ch.B., Keboile Serole¹,
9 M.B., Ch.B., Remy Daroowala¹, M.B., Ch.B., Arshad Taliep¹, M.B., Ch.B., Petri Ahlers⁹, M.B.,
10 Ch.B., Stephanus T. Malherbe⁹, M.B., Ch.B., Rory Bowden^{5,11}, Ph.D., Robin Warren⁹, Ph.D.,
11 Gerhard Walzl⁹, M.B., Ch.B., Laura E. Via^{13,14}, Ph.D., Melanie Bahlo^{5,10}, Ph.D., Karen R.
12 Jacobson^{15,16}, M.D., C. Robert Horsburgh Jr.¹⁶, M.D., Padmini Salgame⁸, Ph.D., David Alland¹⁷,
13 M.D., Clifton Earl Barry III^{1,13,14}, Ph.D., JoAnne L.Flynn¹⁸, Ph.D., Jerrold J Ellner⁸, Ph.D., Robert J
14 Wilkinson^{1,19,20} F.Med.Sci.

15 *equal contribution

16 Affiliations

- 17 1. Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine,
18 University of Cape Town, Observatory 7925, Republic of South Africa
19 2. MRC Clinical Trials Unit at University College London, WC1V 6LJ, United Kingdom
20 3. WHO Collaborating Centre for Tuberculosis Research and Innovation, Institute for Global Health, University
21 College London, WC1E 6JB, United Kingdom
22 4. Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research,
23 Parkville, Victoria 3052, Australia
24 5. Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia.
25 6. Department of Internal Medicine, University Hospital of Zurich, University of Zurich, Switzerland.
26 7. Division of Nuclear Medicine, Department of Medical Imaging and Clinical Oncology, Stellenbosch University,
27 Cape Town, South Africa
28 8. Division of Infectious Diseases, Center for Emerging Pathogens, New Jersey Medical School, Rutgers University,
29 Newark, NJ, USA.
30 9. Department of Science and Technology/National Research Foundation Centre of Excellence in Biomedical
31 Tuberculosis Research, South African Medical Research Council for Tuberculosis Research, Division of
32 Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Health Sciences,
33 Stellenbosch University, Cape Town, South Africa.
34 10. Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville,
35 Victoria 3052, Australia
36 11. Advanced Genomics Facility, Advanced Technology and Biology Division, The Walter and Eliza Hall Institute of
37 Medical Research, Parkville, Victoria 3052, Australia
38 12. Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.

- 39 13. Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of
40 Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
- 41 14. Tuberculosis Imaging Program, Division of Intramural Research, National Institute of Allergy and Infectious
42 Diseases, National Institutes of Health, Bethesda, MD.
- 43 15. Section of Infectious Diseases, Boston University Chobanian and Avedisian School of Medicine and Boston
44 Medical Center, Boston, MA, USA.
- 45 16. Department of Epidemiology, Boston University School of Public Health Boston, MA, USA.
- 46 17. Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, USA.
- 47 18. Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, PA 15261,
48 United States of America
- 49 19. The Francis Crick Institute London NW1 1AT, United Kingdom
- 50 20. Department of Infectious Diseases, Imperial College London W12 0NN, United Kingdom

51

52 **Corresponding author:** Anna Coussens: coussens.a@wehi.edu.au

53 **Abstract**

54 **Background**

55 The evolution of tuberculosis (TB) disease during the clinical latency period remains
56 incompletely understood.

57 **Methods**

58 250 HIV-uninfected, adult household contacts of rifampicin-resistant TB with a negative
59 symptom screen underwent baseline ¹⁸F-Fluorodeoxyglucose positron emission and computed
60 tomography (PET/CT), repeated in 112 after 5-15 months. Following South African and WHO
61 guidelines, participants did not receive preventive therapy. All participants had intensive
62 baseline screening with spontaneous, followed by induced, sputum sampling and were then
63 observed for an average of 4.7 years for culture-positive disease. Baseline PET/CT abnormalities
64 were evaluated in relation to culture-positive disease.

65 **Results**

66 At baseline, 59 (23.6%) participants had lung PET/CT findings consistent with TB of which 29
67 (11.6%) were defined as Subclinical TB, and 30 (12%) Subclinical TB-inactive. A further 83 (33.2%)
68 had other lung parenchymal abnormalities and 108 (43.2%) had normal lungs. Over 1107-person
69 years of follow-up 14 cases of culture-positive TB were diagnosed. Six cases were detected by
70 intensive baseline screening, all would have been missed by the South African symptom-based
71 screening strategy and only one detected by a WHO-recommended chest X-Ray screening strategy.
72 Those with baseline Subclinical TB lesions on PET/CT were significantly more likely to be diagnosed
73 with culture-positive TB over the study period, compared to those with normal lung parenchyma
74 (10/29 [34.5%] vs 2/108 [1.9%], Hazard Ratio 22.37 [4.89-102.47, p<0.001]).

75

76 **Conclusions**

77 These findings challenge the latent/active TB paradigm demonstrating that subclinical disease exists

78 up to 4 years prior to microbiological detection and/or symptom onset. There are important

79 implications for screening and management of TB.

80

81 **Introduction**

82 One quarter of the world's population is considered to have latent tuberculosis (TB) infection
83 (i.e., evidence of immune sensitization in the absence of clinical signs or symptoms of disease).¹
84 The risk of developing disease is elevated for 5-10 years following exposure.²⁻⁴ Conventionally,
85 latent TB is conceived as a state in which *Mycobacterium tuberculosis* (*Mtb*) is successfully
86 contained within microscopic granulomas which limit replication, preventing invasive
87 pathology, symptoms and infectiousness.^{5,6} Active TB disease is considered to arise when
88 granulomatous control fails leading to evident, invasive pathology associated with symptoms,
89 detectable bacilli and infectiousness.⁷ This paradigm strongly influences programmatic
90 management.^{8,9}

91
92 Insight into pathological events during the period of clinical latency is limited. A more nuanced
93 concept of disease evolution that encompasses heterogeneity amongst persons with immune
94 sensitisation with some having evidence of disease in the absence of symptoms has been
95 proposed.^{10,11} Early lung disease is well-described in autopsy studies and animal models and is
96 characterized by a cellular infiltrate spreading bronchogenically.¹²⁻¹⁴ In a previous study we
97 showed that high-resolution anatomical and functional imaging by ¹⁸F-Fluorodeoxyglucose
98 combined positron emission and computed tomography (PET/CT) was highly sensitive to
99 identify pathology consistent with TB disease in asymptomatic HIV-infected, individuals
100 considered to have latent TB, defining an imaging phenotype for subclinical disease.¹⁵

101

102 To further understand TB progression, the aims of this study were to (1) determine the
103 proportion of HIV-uninfected, symptom-free, TB household contacts (HHC) with baseline
104 PET/CT abnormalities suggestive of subclinical TB disease and (2) compare the proportion with
105 and without these abnormalities diagnosed with culture positive TB following intensive
106 respiratory sampling and close follow-up over 5 years without preventive treatment.

107

108

109 **Methods**

110 ***Study design and oversight***

111 A prospective, observational, cohort study was conducted in HIV-uninfected, adult HHC of
112 rifampicin-resistant (RR) TB cases who, consistent with national and international guidelines,
113 were not provided preventive therapy.^{16,17} The study was approved by the human research
114 ethics committees of the University of Cape Town (HREC 449/2014), Boston University (H-
115 35831), Rutgers University (Pro2018001966), and the Division of Microbiology and Infectious
116 Diseases of NIH (DMID 16-0112). This report follows STROBE guidelines for cohort studies.

117

118 ***Recruitment of participants***

119 Recruitment was between November 2014 and September 2017 with follow-up until May 2021.
120 All participants were residents of Khayelitsha, South Africa. Index cases (>15 years old) with RR
121 pulmonary TB consented to a household visit. Adult HHC not on TB treatment were baseline
122 screened following initial consent. Participants further consented to PET/CT imaging and blood
123 sampling (**Supplementary Methods**) if not meeting the following exclusion criteria; HIV
124 infection, symptoms of TB by South African national guidelines (2 weeks cough, fever, weight
125 loss, night sweats¹⁷), clinical signs of TB, acute illness, age >65 years, smoker >30 pack-years,
126 malignancy, chronic lung infection or inflammation, inhaled or systemic steroid use within
127 previous 2 weeks, breast-feeding, pregnant, planning pregnancy, unable to be followed up,
128 uncontrolled diabetes mellitus, unwilling, or at investigator discretion (**Figure 1**).

129

130

131 ***Investigations to diagnose TB***

132 At baseline all participants underwent TB symptom screening, digital chest radiography (CXR).
133 All were invited to produce a sputum sample spontaneously if able (irrespective of symptom
134 screen and CXR status) and then underwent further sputum induction using hypertonic saline
135 until three sputum samples were obtained. All sputum samples were sent for smear, Xpert
136 MTB/RIF and bacterial (MGIT) culture (**Supplementary Methods**). Follow-up was both active
137 and passive. Repeat PET/CT was performed at 5-15 months in 112/250 participants and
138 bronchoscopy and lavage culture performed on 28/112 (**Supplementary Methods**). All
139 participants were actively screened for TB between 23 to 38 months with three sputum
140 samples (induced if needed) and any time before this visit, if they reported TB symptoms
141 during 3-monthly phone calls. The Western Cape Provincial Health Data Centre (PHDC) database
142 was cross-checked for additional cases in May 2021.¹⁸

143

144 Participants were considered to have culture-confirmed TB if any specimen was *Mtb* positive by
145 culture. Participants were considered to have clinically confirmed TB if there was a decision to
146 start TB treatment made by statutory services without a positive culture.

147

148 ***PET/CT classification***

149 Two readers provided independent structured reports, differences were resolved by a third
150 reader. All were blinded to clinical history and microbiological results (**Supplementary**
151 **Methods**). Baseline scans were classified into four mutually exclusive categories based on
152 previous work¹⁵:

- 153 • Radiographically consistent with TB disease (Subclinical TB): Presence of infiltrate
154 and/or FDG-avid nodule(s) within the upper lobes or apical segment of lower lobes.
- 155 • Radiographically consistent with inactive TB (Subclinical TB-inactive): Presence of
156 fibrotic scar(s) within the upper lobes or apical segment of lower lobes.
- 157 • Other parenchymal abnormalities not meeting definitions above.
- 158 • Normal lung parenchyma.

159

160 ***Sample size***

161 Sample size was governed by the expected proportion with PET/CT parenchymal abnormalities
162 consistent with Subclinical TB or Subclinical TB-inactive. We predicted 50% would become
163 infected following exposure, of whom 30-40% would have abnormalities based on prior
164 experience.¹⁵ We therefore expected 15-20% to have PET/CT abnormalities with a sample of
165 250 providing precision of approximately $\pm 5\%$ with 95% confidence.

166

167 ***Consideration for different screening strategies***

168 As the intensity of baseline screening could affect the likelihood of culture positive cases being
169 identified during follow-up, to help interpret the findings within a real-world context, we
170 considered the culture positive events in relation to 3 baseline screening approaches of varying
171 stringency.

- 172 • Study screening approach: 3 x sputum culture, induced if needed, irrespective of
173 symptom screen or CXR findings.

- 174 • South African national guidelines: Spontaneous sputum Xpert investigation at baseline
175 only if symptom screen positive.
- 176 • WHO systematic screening guidelines (2021): Spontaneous sputum Xpert investigation
177 at baseline only if symptom screen positive or CXR suggestive of TB.

178

179 ***Statistical analysis***

180 Statistical analysis was conducted in Stata ver. 17.0 (StataCorp). Non-parametric data was
181 compared using Mann-Whitney *U* test or Kruskal Wallis with Dunn's *post hoc* test and
182 parametric data compared using t-test or ANOVA. Proportions were compared by χ^2 or Fisher's
183 exact test. We used Cox proportional-hazards regression to assess the impact of PET/CT
184 classification on time to culture positivity, the proportional hazards assumption was assessed
185 by Schoenfeld residuals. Multivariate modelling was undertaken to assess the impact of
186 covariates (previous TB, age, sex, QuantiFERON status and hours of contact/day with index) by
187 forward selection and assessment by Likelihood Ratio test. Only participants with complete
188 data for these variables were included (247 participants).

189

190 **Results**

191 **Recruitment**

192 983 household members of 145 index cases with RR-TB were identified, of whom 271 (28%)
193 were <18 years old. 511 adult participants were screened for eligibility. 261 (51%) participants
194 were excluded including 145 with HIV infection and 49 TB symptom positive (**Figure 1**).

195

196 **Clinical characteristics**

197 250 HIV uninfected participants were enrolled: median age 30 years (IQR 23-43), 60% women.
198 Thirty-four (13.6%) had a previous TB history (median 10 years prior (IQR 7-24). All participants
199 had a negative symptom screen. 248 had a valid QuantiFERON-TB Gold (QFT-G) result and 241 a
200 QuantiFERON-TB Plus (QFT-Plus) result. 205 (82%) were positive by at least one test, thus
201 defined as having latent TB infection. 249 participants underwent CXR, 37 (14.9%) had changes
202 suggestive of TB (**Table 1**). 160 (64%) produced a sputum sample spontaneously and 249
203 following induction (237 (94.8%) provided a total of three samples). The cohort was followed
204 for 1107 person-years (median 4.7 years). 194 (77.6%) had repeat sputa between 23-38 months
205 and 247 (98.8%) were tracked through the PHDC. One participant was not followed up in either
206 way.

207

208 **Baseline PET/CT findings in asymptomatic household contacts**

209 On baseline PET/CT imaging, 142 (56.8%) had abnormalities within the lung parenchyma: 29
210 (11.6%) Subclinical TB, 30 (12%) Subclinical TB-inactive, 83 (33.2%) other abnormalities. 108
211 (43.2%) had no lung abnormalities (**Table 1 and Supplementary Table S1**). 105 participants
212 (42%) had mediastinal and hilar lymph node abnormalities, of whom 53 had FDG-avid lymph
213 nodes (**Table 1 and detailed in Supplementary Appendix**). Those with Subclinical TB and
214 Subclinical TB-inactive had greater total lymph node lesions and maximum visual score
215 (≤ 0.005).

216

217 Approximately half (48.3-50%) of those categorised as Subclinical TB and Subclinical TB-inactive
218 had a previous TB history, compared to 2.4-2.8% of those with normal or other lung lesions
219 ($p < 0.001$). Of the 216 with no history of TB, 15 (6.9%) had Subclinical TB and 15 (6.9%)
220 Subclinical TB-inactive. Of these, 7/15 (46.7%) and 1/14 (7.1%; one no CXR), respectively, had a
221 CXR reported as suggestive of TB (**Supplementary Table S2**).

222

223 **Risk of culture positivity in relation to baseline PET/CT findings**

224 Over the study period 14/250 (5.6%) were diagnosed with culture positive TB (**Table 1**). Six
225 were diagnosed following intensive baseline screening and eight during follow-up after a
226 median of 32 months (IQR 9.5-37.5), of which only 3/8 (37.5%) were symptomatic at follow-up
227 diagnosis (**Supplementary Table S3**). Of the six baseline culture positive participants, none
228 would have been diagnosed if screened according to South African national guidelines and only
229 1 diagnosed if screened following WHO guidelines (**Figure 2**). Four additional participants were
230 treated for TB during follow-up, two with positive Xpert alone, and two clinically diagnosed. A
231 further four had a positive Xpert alone without symptoms and were not treated (with no
232 progression observed during follow-up). These eight patients were not included in the primary
233 analysis but in two sensitivity analyses (**Figure 3 and Supplementary Results-2.5**). Individual
234 longitudinal imaging and clinical findings for all 22 participants are shown in **Supplementary**
235 **Figure S1**.

236

237 Of those with Subclinical TB on PET/CT 10/29 (34.5%) were ultimately diagnosed culture-
238 positive (all when still asymptomatic), compared to 1/30 (3.3%) with Subclinical TB-inactive,

239 1/83 (1.2%) with other abnormalities and 2/108 (1.83%) with normal lungs (**Table 1**). The four
240 culture-positive cases that did not have Subclinical TB were all drug-sensitive. Conversely, 7/10
241 culture-positive Subclinical TB cases had drug resistance similar to the index case; and three
242 had index and contact isolates available with linkage confirmed by whole genome sequencing
243 (**Supplementary Table S3**). The remaining 3/10 were drug sensitive. Comparison of the
244 demographic and radiological features of those with Subclinical TB who did, and did not,
245 develop culture positive TB is shown in **Supplementary Table S4**.

246

247 Compared to those with normal lung parenchyma, those with Subclinical TB on PET/CT (all of
248 whom would not have been picked up by South African screening guidelines) were at
249 significantly increased risk of culture positive TB, Hazard Ratio (HR) 22.37 (4.89-102.47),
250 $p < 0.001$. In a model adjusting for previous TB, the HR increased to 39.7 (8.42-187.33), $p < 0.001$
251 (**Table 2 and Figure 3C-D**). Excluding one participant who would have been diagnosed with the
252 WHO screening approach or six participants diagnosed culture positive by the study approach
253 at baseline, Subclinical TB on baseline PET/CT remained significantly associated with
254 development of culture positive TB during follow-up, HR 21.29 (4.59-98.80) $p < 0.001$ and HR
255 10.65 (1.94-58.22) $p = 0.006$, respectively. Expanding the TB case definition to include the four
256 additional treated TB cases and then the four additional untreated TB cases had little impact on
257 HR for Subclinical TB on PET/CT, HR 28.10 (6.27-125.85) and HR 20.65 (5.87-72.68), respectively
258 (**Figure 3E-F and Supplementary Results-2.5**). By contrast those with positive QFT were not at
259 significant increased risk of culture positive TB compared to those with a negative QFT HR 2.76
260 (0.36-21.13), $p = 0.33$ (**Figure 3A-B and Supplementary Results-2.4**).

261

262 **Performance of baseline PET/CT findings to predict progression from infection to disease**

263 Thirteen of the 14 confirmed with culture-positive TB over the study period were clinically
264 defined by QFT as having latent TB infection at baseline of which 10 (76.9%) had Subclinical TB
265 on baseline PET/CT. In those with a clinical diagnosis of latent TB infection in whom TB disease
266 was microbiologically excluded by the WHO screening approach, performance of PET/CT-
267 defined Subclinical TB for culture positive TB over a 3-year period was; PPV 33.3% (95%CI
268 16.5%-54%), sensitivity 90% (95%CI 55.5%-99.7%) and specificity 90.7% (95% CI 85.7%-94.4%)
269 exceeding the optimal WHO target product profile (TPP) characteristics for a test that predicts
270 progression from TB infection to active disease.¹⁹

271

272 **Change in parenchymal lesions over time**

273 112/250 participants had a repeat PET/CT after a median of 203 days (IQR 188-287), and of
274 these 110 had not received any TB treatment prior to repeat PET/CT. The proportion of
275 untreated participants showing a noticeable change in parenchymal lesions (**Supplementary**
276 **Methods**) was significantly different in relation to the nature of lesions at baseline ($p < 0.001$).
277 Three quarters (12/16) of those with Subclinical TB showed substantial (greater than minimal)
278 changes over time (6 worsening/mixed, 6 improving), compared to 23.5% (4/17) of those with
279 Subclinical TB-inactive lesions (4 worsening/mixed) and 17.5% (7/40) with other lesions (5
280 improving, 2 worsening/mixed). By contrast there was no significant difference in noticeable
281 changes in lymph nodes related to the nature of parenchymal lesions at baseline ($p = 0.136$)

282 **(Supplementary Figure S2).** Twenty-eight participants underwent bronchoalveolar lavage
283 following the repeat PET/CT all of which were culture negative (**Supplementary Results-2.2**).
284
285 Eight of those who had a repeat PET/CT after a median of 248.5 days [IQR 192.5-371.0] were
286 subsequently treated for TB (5 culture positive and 3 clinically diagnosed) a median 669 days
287 [IQR 222-842]) after the repeat scan. Between baseline and second PET/CT, 2 showed
288 improvement, 3 mixed, 3 minimal improvement/no change. Four had a third scan at the time of
289 TB diagnosis, 2 showed improvement and 2 worsening, compared to second PET/CT (**Figure 2**
290 **and Supplementary Figure S1B-C**).
291

292 **Discussion**

293 This study is the largest to systematically use high resolution imaging in asymptomatic contacts
294 of TB and the first with prolonged follow-up in the absence of treatment and builds on our
295 previous work to characterise and develop definitions for subclinical TB lesions.^{15,20} We found
296 that over three-quarters (76.9%) of asymptomatic, HIV-uninfected adults with a clinical
297 diagnosis of latent TB who were confirmed to have culture positive pulmonary TB over a 5-year
298 period had radiologically apparent infiltrative disease at baseline. Overall, of the 11.6%
299 (29/250) who had baseline radiographic findings consistent with Subclinical TB disease, 34.5%
300 (10/29) were subsequently diagnosed with culture positive TB, with 7/10 (70%) having drug
301 resistance/WGS concordant with the index case. We have shown that slow evolution of
302 radiographically evident disease pathology can occur over many years without apparent clinical
303 manifestations.

304
305 Current tests for latent TB infection poorly predict the development TB disease resulting in high
306 numbers needed to be treated to prevent a case of disease. The WHO have developed a TPP for
307 diagnostic tests that could better predict TB progression.¹⁹ In those with a clinical diagnosis of
308 latent TB in whom TB disease was excluded, subclinical changes on PET/CT had a sensitivity of
309 90% and specificity of 91% for culture positive TB over three years exceeding the TPP optimal
310 performance characteristics. Whilst such performance has not previously been achieved,
311 PET/CT is not a feasible routine diagnostic. However, our findings do support its use as a
312 reference standard to identify and validate blood-based biomarkers to accelerate development
313 of such a test.

314

315 In our study, TB diagnosis was frequently made by intensive active case detection and induced
316 sputum collection. It is conjectural what the natural history of such cases would have
317 subsequently been; some may have self-healed, whilst it is also plausible that others would
318 have eventually presented symptomatically. However, by contextualising our results with
319 different screening scenarios we demonstrate that asymptomatic culture confirmable cases are
320 being missed routinely. Our results mirror findings from the macaque model of TB from which
321 a subclinical “percolator” phenotype has previously been described.²¹ It is also possible that
322 individuals with subclinical disease could intermittently shed bacilli in respiratory secretions
323 thus posing a transmission risk; in a recent study by Williams *et al* five adults screened in South
324 Africa with negative sputum culture and a positive facemask *Mtb* DNA sample all had
325 abnormalities on PET/CT.²²

326

327 There are limitations to our study; it was conducted in a high TB burden setting in HIV-
328 uninfected, adult contacts of DR-TB and hence we can only speculate on how our findings relate
329 to other populations. Disease trajectories in the context of immunosuppression (e.g. with HIV
330 co-infection) differ, potentially with higher proportions of those with Subclinical TB progressing.
331 In low-incidence settings the likelihood of participants having a previous history of TB and
332 having additional TB exposure during follow-up would be low. In our study the four cases of
333 culture-positive TB in those without Subclinical TB changes were drug-sensitive (i.e. unlikely
334 related to index) with one case being QFT-negative at baseline and the remaining three
335 occurring after 32 months suggesting that exposures after the baseline PET-CT may have

336 contributed in these instances. Fourteen percent of our cohort had a previous history of TB.

337 Residual changes of previously treated disease are difficult to distinguish from changes

338 associated with new disease, however the risk of culture-confirmed disease in those with

339 Subclinical TB was higher in younger individuals and those without previous TB history. For

340 these reasons in a low incidence setting the performance of PET/CT may be improved.

341

342 Our results challenge present concepts of the evolution of human TB disease having

343 implications for diagnostic and intervention strategies. Although 82% had a diagnosis of latent

344 TB infection, the 11.6% with baseline Subclinical TB carried most of the 5-year disease risk.

345 Developing diagnostics and therapeutic approaches that target this population would therefore

346 be likely to result in a reduction in the numbers needed to treat to prevent a case of clinical

347 disease and enable TB care and prevention strategies to drastically limit onwards transmission

348 and potential post-TB sequelae.

349

350 **Acknowledgements**

351 Funding for this study was provided by the South African Medical Research Council (SAMRC;
352 SHIP-02- 2013), NIH (U19AI111276 and R01106804), Bill and Melinda Gates Foundation
353 (37822), Wellcome (203135Z/16/Z) and WEHI (BDO innovation fund and philanthropy). RJW is
354 supported the Francis Crick Institute which receives funding from Wellcome (CC2012), Cancer
355 Research UK (CC2012) and MRC (FCC2012); AKC is supported by the NHMRC (GNT2020750); MB
356 is supported by the NHMRC (GNT1195236); LEV and CEB were supported by the Division of
357 Intramural Research, NIAID, NIH. The authors thank the Provincial Health Department of the
358 Western Cape for use of the Site B health facility in Khayelitsha and for access to the Provincial
359 Health Data Centre, with particular thanks to Mariette Smith and Nicki Tiffin. The authors thank
360 Stephen Wilcox of the Advanced Genomics Facility at the Walter and Eliza Hall Institute of
361 Medical Research for support and assistance in this work, which was made possible through
362 Victorian State Government Operational Infrastructure Support and Australian Government
363 NHMRC IRIISS. For the purposes of open access, the authors have applied a CC-BY public
364 copyright to any author-accepted manuscript arising from this submission.

365 **References**

- 366 1. Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-
367 estimation Using Mathematical Modelling. *PLoS Med.* 2016;13(10):e1002152.
- 368 2. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. *Bibl*
369 *Tuberc.* 1970;26:28-106.
- 370 3. Borgdorff MW, Sebek M, Gesskus RB, Kremer K, Kalisvaart N, van Soolingen D. The
371 incubation period distribution of tuberculosis estimated with a molecular
372 epidemiological approach. *Int J Epidemiol.* 2011;40(4):964-970.
- 373 4. Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. *BMJ.*
374 2018;362:k2738.
- 375 5. Centre for Disease Control and Prevention. Basic TB Facts: Latent TB Infections and TB
376 Disease. <https://www.cdc.gov/tb/topic/basics/tbinfectiondisease.htm>. Accessed 29th
377 August, 2021.
- 378 6. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent *Mycobacterium tuberculosis*
379 infection. *N Engl J Med.* 2015;372(22):2127-2135.
- 380 7. Boom WH, Schaible UE, Achkar JM. The knowns and unknowns of latent *Mycobacterium*
381 *tuberculosis* infection. *J Clin Invest.* 2021;131(3).
- 382 8. World Health Organization. *WHO Consolidated Guidelines on Tuberculosis - Module 4:*
383 *Treatment - Drug-susceptible tuberculosis treatment.* Geneva2022.
- 384 9. World Health Organization. *WHO Consolidated Guidelines on Tuberculosis - Module 1:*
385 *Prevention - Tuberculosis Preventive Treatment.* Geneva2020.

- 386 10. Esmail H, Barry CE, 3rd, Young DB, Wilkinson RJ. The ongoing challenge of latent
387 tuberculosis. *Philos Trans R Soc Lond B Biol Sci.* 2014;369(1645):20130437.
- 388 11. Barry CE, 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking
389 the biology and intervention strategies. *Nat Rev Microbiol.* 2009;7(12):845-855.
- 390 12. Hunter RL. Pathology of post primary tuberculosis of the lung: An illustrated critical
391 review. *Tuberculosis.* 2011;91(6):497-509.
- 392 13. Opie EL, Aronson JD. Tubercule Bacilli in Latent Tuberculosis Lesions and in Lung Tissue
393 without Tuberculosis Lesions. *Arch Pathol.* 1927;4(1):1-21.
- 394 14. Lin PL, Ford CB, Coleman MT, et al. Sterilization of granulomas is common in active and
395 latent tuberculosis despite within-host variability in bacterial killing. *Nat Med.*
396 2014;20(1):75-79.
- 397 15. Esmail H, Lai RP, Lesosky M, et al. Characterization of progressive HIV-associated
398 tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed
399 tomography. *Nat Med.* 2016;22(10):1090-1093.
- 400 16. World Health Organization. *Guidelines on the management of latent tuberculosis*
401 *infection.* World Health Organisation;2015.
- 402 17. Department of Health Republic of South Africa. *National Tuberculosis Management*
403 *Guidelines.* 2014.
- 404 18. Boulle A, Heekes A, Tiffin N, et al. Data Centre Profile: The Provincial Health Data Centre
405 of the Western Cape Province, South Africa. *Int J Popul Data Sci.* 2019;4(2):1143.

- 406 19. World Health Organization. *Development of a Target Product Profile (TPP) and a*
407 *framework for evaluation for a test for predicting progression from tuberculosis infection*
408 *to active disease*. Geneva: World Health Organization;2017.
- 409 20. Yoon SH, Goo JM, Yim JJ, Yoshiyama T, Flynn JL. CT and (18)F-FDG PET abnormalities in
410 contacts with recent tuberculosis infections but negative chest X-ray. *Insights Imaging*.
411 2022;13(1):112.
- 412 21. Lin PL, Rodgers M, Smith L, et al. Quantitative comparison of active and latent
413 tuberculosis in the cynomolgus macaque model. *Infect Immun*. 2009;77(10):4631-4642.
- 414 22. Williams CM, Abdulwhhab M, Birring SS, et al. Exhaled *Mycobacterium tuberculosis*
415 output and detection of subclinical disease by face-mask sampling: prospective
416 observational studies. *Lancet Infect Dis*. 2020;20(5):607-617.
- 417
- 418

419 **Tables**

Table 1. Baseline characteristics, clinical and radiographic findings, and TB outcomes of HHC who underwent PET/CT

Variable	All HHC n=250	Subclinical TB n=29	Subclinical TB- Inactive n=30	Other lung lesions n=83	Normal lung n=108	p-value
Demographics						
Age (years)	30 (23-43)	43 (30-50)^{1,2}	41 (28-54)^{1,2}	28 (23-39)	27 (22-40)	<0.001
Sex (Female)	150 (60%)	14 (48.3%)	17 (56.7%)	53 (63.9%)	66 (61.1%)	0.5
Previous TB	34 (13.6%)	14 (48.3%)	15 (50%)	2 (2.4%)	3 (2.8%)	<0.001
Daily index contact	208 (83.2%)	24 (82.8%)	26 (86.7%)	72 (86.7%)	86 (79.6%)	0.57
>6hrs/day with index	96/249 (38.5%)	14 (48.3%)	10 (33.3%)	37 (44.6%)	35/107 (32.7%)	0.23
1st degree relative	106 (42.4%)	9 (31.0%)	19 (63.3%)	39 (47.0%)	39 (36.1%)	0.11
Ever smoked	85 (34%)	12 (41.3%)	15 (50%)	22 (26.5%)	36 (33.3%)	0.10
BMI	28.2 (22.2-34)	24.0 (19.8-29.3)^{2,3}	25.5 (21.3-34.6)^{2,3}	29.2 (22.37-33.49)	28.5 (23.5-35.4)	0.02
Clinical Investigations						
CXR TB Suggestive	37/249 (14.9%)	16 (55.2%)	10/29 (34.5%)	2 (2.4%)	9 (8.3%)	<0.001
Proportion QFN+ Gold or Plus	205/248 (82.7%)	28 (96.6%)	27 (90.0%)	72 (86.7%)	78/106 (73.6%)	0.007
QFN Nil IFN γ (IU/ml)	0.03 (0.00-0.13)	0.08 (0.01-0.14)	0.01 (0.00-0.08)	0.03 (0.00-0.18)	0.03 (0.00-0.12)	0.17
QFN Gold Ag-Nil IFN γ (IU/ml)	6.82 (0.66-41.83)	14.62 (3.11-56.85)¹	10.2 (1.4-57.0)¹	7.6 (0.9-48.0)¹	3.79 (0.1-19.1)	0.01
QFN Plus-1 Ag-Nil IFN γ (IU/ml)	5.53 (0.45-29.57)	12.90 (2.39-36.93)¹	10.70 (1.95-34.69)¹	5.53 (0.95-40.26)¹	2.78 (0.15-16.57)	0.02
QFN Plus-2 Ag-Nil IFN γ (IU/ml)	6.26 (0.59-33.37)	18.01 (2.58-44.46)¹	10.76 (1.80-33.72)¹	6.49 (0.76-48.44)¹	3.48 (0.24-20.50)	0.02
CRP (mg/L)	3 (1-7)	4 (1-11)	3.5 (1-7)	2.3 (1-5)	2 (1-7)	0.44
CRP \geq 10 mg/L	40/247 (16.2%)	8 (27.6%)	4 (13.3%)	11/82 (13.4%)	17/106 (16.0%)	0.33
ESR (mm/Hr)	15 (5-30)	20 (8-33)	20.5 (9-31)	11 (4-30)	13.5 (3-26)	0.10
WCC (x10 ⁹ /L)	5.91 (4.88-7.54)	7.04 (5.97-8.01)	5.75 (5.06-7.18)	5.78 (4.54-7.39)	5.85 (4.74-7.62)	0.06
Neut (x10 ⁹ /L)	3.28 (2.27-4.54)	4.00 (3.39-5.14)^{1,2,3}	3.25 (2.33-4.46)	2.94 (2.18-4.64)	3.19 (2.25-4.42)	0.04
N:L	1.59 (1.12-2.24)	2.21 (1.60-2.67)^{1,2,3}	1.56 (1.21-2.32)	1.50 (1.10-2.22)	1.60 (1.07-2.09)	0.03
N:M	8.04 (6.21-10.53)	9.17 (7.13-12.24)	7.24 (5.81-10.47)	8.15 (6.49-10.40)	7.99 (6.11-10.16)	0.24
L:M	5.09 (4.00-6.49)	4.50 (3.47-5.85)	5.31 (3.44-6.65)	4.99 (4.31-6.77)	5.15 (4.11-6.26)	0.24
PET/CT Imaging Findings						
Lung total lesions	1 (0-3)	6 (4-10)^{1,2}	5 (2-8)^{1,2}	1 (1-3)	0 (0-0)	<0.001
total infiltrates	0 (0-0)	1 (0-2)^{2,3}	0 (0-0)	0 (0-0)	NA	<0.001
total fibrotic scars	0 (0-2)	1 (0-2.5)^{2,3}	2 (1-3)²	0 (0-0)	NA	<0.001
total nodules	1 (0.75-3)	3 (1-5)²	1 (0-4.25)	1 (1-2)	NA	0.028
total cavities	0 (0-0)	0 (0-0.5)^{2,3}	0 (0-0)	0 (0-0)	NA	<0.001
Lung largest lesion size (mm)	11.15 (4.82-32.55)	44.19 (26.2-56.3)²	33.3 (26.5-45.7)²	5 (4-9.66)	NA	<0.001
Lung maximum VS	0 (0-1)	3 (2-3)^{2,3}	0 (0-1)²	0 (0-0)	NA	<0.001
Lung SUV _{max}	1.29 (0.94-1.89)	2.63 (1.77-5.77)^{2,3}	1.45 (1.18-1.9)²	1.07 (0.81-1.35)	NA	<0.001
Lung HU _{max}	115 (-43-481)	185 (88-648)²	670.5 (140-1123)²	7.5 (-129-179)	NA	<0.001
LN total lesions	0 (0-2)	2 (0-3)^{1,2}	1.5 (0-3)^{1,2}	0 (0-2)	0 (0-1)	<0.001
FDG-avid LN present	53 (21.2%)	16 (55.2%)	12 (40%)	15 (18.07%)	10 (9.3%)	<0.001
Largest abnormal LN (mm)	8.5 (5.8-11.2)	11.0 (8.35-13.4)	8.0 (5.42-12.2)	8.4 (5.0-10.3)	8.0 (5.4-10.0)	0.06
LN maximum VS	1.5 (1-3)	3 (2-3)^{1,2,3}	2 (1-3)¹	1 (1-2)	1 (1-2)	0.005
LN SUV _{max}	2.63 (1.90-4.10)	3.51 (2.63-4.87)^{1,2}	2.60 (2.19-3.53)	2.25 (1.60-3.36)	2.11 (1.74-3.46)	0.02
LN HU _{max}	549.5 (134.5-1041.5)	274.5 (94.5-7685)	786 (158-1092)	488 (136-1013)	658 (208-1115)	0.25
TB Outcome						
Culture positive at baseline (treated)	6 (2.4%)	6 (20.7%)	0 (0%)	0 (0%)	0 (0%)	<0.001
Culture positive at follow-up (treated)	8/249 (3.2%)	4 (18.8%)	1 (3.3%)	1 (1.2%)	2/107 (1.9%)	0.007
Clinical TB at follow-up (treated)	4/249 (1.6%)	2 (6.9%)	1 (3.3%)	1 (1.2%)	0/107 (0%)	0.01
Xpert positive culture negative (not treated, asymptomatic)	4 (1.6%)	1 (3.4%) ⁵	2 (6.7%) ^{4,5}	0 (0%)	1 (0.9%) ⁴	0.04
Any TB or Mtb detected over study period	22 (8.2%)	13 (44.8%)	4 (13.3%)	2 (2.5%)	3 (2.8%)	<0.001
Symptoms at Any treated TB diagnosis	7/18 (38.9%)	2/12 (16.7%)	2/2 (100%)	2/2 (100%)	1/2 (50%)	0.03
Symptoms at culture positive TB diagnosis	3/14 (21.4%)	0/10 (0%)	1/1 (100%)	1/1 (100%)	1/2 (50%)	0.01

421 Values are n (%) or median (IQR). Denominator values are indicated in the column descriptor, or
422 indicated in a cell when values were missing. Relationship between PET/CT categories and baseline
423 characteristics analysed for categorical variables analysed by χ^2 or Fisher's exact test, for numerical
424 variables by Kruskal Wallis with *post hoc* analysis using Dunn's multiple comparison testing. Bold and
425 superscript number indicates which post-hoc numerical comparisons are significantly different ($p < 0.05$): 1
426 = in comparison with no lung lesions, 2 = in comparison with Other lung lesions, 3 = in comparison with
427 Subclinical-inactive TB. BMI, body mass index; Clinical TB, TB symptom positive *Mtb* culture and Xpert
428 negative; CRP, C-reactive protein; CXR, chest X-ray; ESR, erythrocyte sedimentation rate; F, female; HU_{max},
429 maximum Hounsfield units; IFN γ , interferon-gamma; LN, lymph node; Neut, neutrophil; N:L,
430 neutrophil:lymphocyte ratio in blood; N:M, neutrophil:monocyte ratio in blood; QFN+, QuantiFERON
431 positive; SUV_{max}, maximum standardised uptake value; VS, visual score; WCC, whole cell count; Xpert,
432 GeneXpert version 3.0: superscript 4 = detected at baseline, 5 = detected at follow-up.

433

434

Table 2. Univariate and multivariate analyses of the risk to develop culture positive TB over the study period due to baseline PET/CT parenchymal abnormalities and main covariates. N=247

Variable	Category	Univariate		Multivariate model adjusting for previous TB	
		Hazard Ratio (95% CI)	p value	Hazard Ratio (95% CI)	p value
Baseline PET/CT	Normal Lung	REF		REF	
	Subclinical TB	22.37 (4.89-102.47)	<0.001	39.7 (8.42-187.33)	<0.001
	Subclinical TB-Inactive	1.73 (0.16-19.08)	0.65	2.83 (0.25-31.5)	0.40
	Other lung abnormalities	0.63 (0.06-6.90)	0.70	0.62 (0.06-6.87)	0.70
Previous TB	No	REF		REF	
	Yes	1.06 (0.24-4.75)	0.94	0.19 (0.04-0.87)	0.03
Age	Per year	1.01 (0.97-1.05)	0.77		
Sex	Female	REF			
	Male	1.14 (0.39-3.27)	0.81		
Hours of contact with index	≤6hours/day	REF			
	>6 hours/day	2.10 (0.73-6.05)	0.17		
Any QuantiFERON	Negative	REF			
	Positive	2.76 (0.36-21.13)	0.33		

435
436

437 **Figure legends**

438 **Figure 1. Study flow diagram**

439 Shows number of individuals screened, excluded, consented and followed up.

440 Cult= culture, micro=microscopy

441

442 **Figure 2. Difference in TB diagnosis according to different screening and follow-up**
443 **approaches and PET/CT images of those diagnosed.**

444 Panels A to D show diagrammatic representation of the cohort by previous TB history and
445 radiographic evidence of subclinical TB showing proportion with confirmed TB with different
446 screening and follow-up approaches: (Panel A) South African guideline: Sputum investigation
447 only if TB symptoms; (Panel B) WHO recommended approach using CXR with spontaneous
448 sputum investigation only x-ray abnormal or symptoms; (Panel C) Intensive sputum
449 investigation at baseline with 3x sputum (induced if needed); (Panel D) Intensive sputum
450 investigation at baseline with follow-up over 5 years. Each of the 250 participants is
451 represented by a circle with outline colour showing baseline PET/CT grouping (Subclinical –
452 orange, Subclinical-inactive – yellow, no/other lesions – black). The circle is filled when TB is
453 confirmed. The proportion with positive a Quantiferon test (QFT+) (i.e. with a clinical diagnosis
454 of latent TB) and the proportion with previous TB is also represented. Cult+ = culture positive,
455 f/u = follow-up. Panel E shows axial sections of fused FDG-PET/CT of the 6 culture positive
456 participants at baseline. Panel F shows axial sections of fused FDG-PET/CT at baseline (top row),
457 second PET/CT after 6-12 months (middle row) and at TB diagnosis (bottom row) of 2
458 participants finally diagnosed with TB at 32 (left) and 34 (right) months. Outline colour denotes;
459 Black = baseline, Green = lesion improves or no change, Red = lesion worsens.

460


461 **Figure 3. Survival curves for culture positive TB diagnosis according QuantiFERON or PET/CT**
462 **findings**

463 Survival curves showing development of TB over time by QuantiFERON status inducing (Panel A)
464 or excluding (Panel B) those with no previous history of TB. Survival curves showing
465 development of TB over time by nature of baseline radiography inducing (Panel C) or excluding
466 (Panel D) those with no previous history of TB. Survival curves showing development of any
467 treated TB (Panel E) or any treated TB and untreated Xpert-positive TB (Panel F) over time by
468 nature of baseline radiography inducing those with no previous history of TB.

469

470


471 **Figure 1**




472

473

474 **Figure 2**



476 **Figure 3**



477